Elicio Therapeutics, Inc. 8K

Elicio Therapeutics reported Q2 2026 results, outlined mixed but potentially supportive clinical data for ELI-002 7P, detailed upcoming Phase 1 combination trials in pancreatic cancer, and disclosed recent financings that extend its cash runway into Q1 2027.

Elicio Therapeutics, Inc. reported its second quarter 2026 financial results and provided corporate and clinical updates, highlighting multiple complete responses seen with ELI-002 7P plus subsequent checkpoint inhibition in metastatic KRAS-driven pancreatic cancer, the failure of its Phase 2 AMPLIFY-7P trial to meet its primary endpoint but ongoing subgroup analyses to refine a Phase 3 adjuvant PDAC strategy, the planned initiation in Q4 2026 of a Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer, the activation of an investigator-initiated neoadjuvant Phase 1 trial led by Memorial Sloan Kettering Cancer Center, and a $15 million registered direct financing in July 2026 that extends its cash runway into the first quarter of 2027, alongside reporting a Q2 2026 net loss of $8.2 million and cash and cash equivalents of $23.5 million as of June 30, 2026.

Filing Facts

CIK

1601485

Ticker

-

Form

8K

Source Type

sec

Accession

0001601485-26-000055

Alert Tier

6